Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10313013 | 0.91 | ESR2 (0.57) | ESR2NR1H2GRM5MAPTGPR119 | |
| SCHEMBL25085668 | 0.91 | ESR2 (0.57) | ESR2NR1H2GRM5MAPTGPR119 | |
| SCHEMBL30207713 | 0.86 | ESR2 (0.55) | ESR2NR1H2GRM5MAPTGPR119 | |
| SCHEMBL8055171 | 0.86 | ESR2 (0.55) | ESR2NR1H2GRM5MAPTGPR119 | |
| SCHEMBL30207688 | 0.85 | NR1H2 (0.56) | ESR2NR1H2GRM5MAPTGPR119 | |
| SCHEMBL2080340 | 0.85 | NR1H2 (0.56) | ESR2NR1H2GRM5MAPTGPR119 | |
| SCHEMBL13568080 | 0.85 | ESR2 (0.51) | ESR2NR1H2GRM5MAPTGPR119 | |
| SCHEMBL8056922 | 0.84 | GRM5 (0.51) | ESR2NR1H2GRM5MAPTGPR119 | |
| SCHEMBL13568077 | 0.83 | ESR2 (0.49) | ESR2NR1H2GRM5MAPTGPR119 | |
| SCHEMBL4198464 | 0.83 | NR1H2 (0.51) | ESR2NR1H2GRM5MAPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | disclosed |
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | disclosed |
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | disclosed |
| WO-2008009125-A9 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | NPS ALLELIX CORP (CA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008009125-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | HTR2C, HTR2A, HTR5A | ESR2 550/4885NR1H2 873/4885GRM5 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.